1201657-89-7 Usage
Uses
Used in Organic Synthesis:
Tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate serves as a valuable intermediate in organic synthesis, where its unique structural features allow for the creation of a wide range of chemical products. Its reactivity and functional groups make it suitable for various synthetic pathways, facilitating the formation of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate is used as a key building block for the synthesis of potential drug candidates. Its molecular structure can be fine-tuned to target specific biological receptors or enzymes, contributing to the development of new therapeutic agents.
Used in Drug Discovery:
Tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate plays a crucial role in drug discovery, where it can be employed to construct novel compounds with potential pharmacological activity. Its presence in a molecule can influence the compound's binding affinity, selectivity, and overall drug-like properties, making it an important component in the quest for new medicines.
Used in Pharmaceutical Development:
As a component in pharmaceutical development, tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate is used to create molecules with therapeutic potential. Its incorporation into drug candidates can lead to the discovery of new treatments for various diseases and conditions, highlighting its importance in advancing healthcare.
Used in Agrochemical Production:
Tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate also finds application in the agrochemical industry, where it can be used to develop new pesticides, herbicides, or other agricultural chemicals. Its chemical properties allow for the design of effective compounds that can protect crops and enhance agricultural productivity.
Check Digit Verification of cas no
The CAS Registry Mumber 1201657-89-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,6,5 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1201657-89:
(9*1)+(8*2)+(7*0)+(6*1)+(5*6)+(4*5)+(3*7)+(2*8)+(1*9)=127
127 % 10 = 7
So 1201657-89-7 is a valid CAS Registry Number.
1201657-89-7Relevant academic research and scientific papers
NAPHTHYRIDINES AS INHIBITORS OF HPK1
-
Paragraph 1776; 1777, (2018/10/21)
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
Liang, Jun,Labadie, Sharada,Zhang, Birong,Ortwine, Daniel F.,Patel, Snahel,Vinogradova, Maia,Kiefer, James R.,Mauer, Till,Gehling, Victor S.,Harmange, Jean-Christophe,Cummings, Richard,Lai, Tommy,Liao, Jiangpeng,Zheng, Xiaoping,Liu, Yichin,Gustafson, Amy,Van der Porten, Erica,Mao, Weifeng,Liederer, Bianca M.,Deshmukh, Gauri,An, Le,Ran, Yingqing,Classon, Marie,Trojer, Patrick,Dragovich, Peter S.,Murray, Lesley
supporting information, p. 2974 - 2981 (2017/05/31)
A high-throughput screening (HTS) of the Genentech/Roche library identified a novel, uncharged scaffold as a KDM5A inhibitor. Lacking insight into the binding mode, initial attempts to improve inhibitor potency failed to improve potency, and synthesis of
PROTEIN KINASE INHIBITORS
-
Paragraph 0184, (2015/02/18)
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
PROTEIN KINASE INHIBITORS
-
, (2013/04/25)
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
-
Page/Page column 122, (2010/01/07)
The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
